Tesamorelin: What It Is, FDA-Approved Use & What Research Shows
A physician-guided explanation of tesamorelin, visceral fat, growth hormone and IGF-1—including what it is actually FDA approved for and where popular weight-loss claims go beyond the evidence.
Tesamorelin is a synthetic growth hormone-releasing hormone (GHRH) analog that stimulates the pituitary gland to release endogenous growth hormone. Its FDA-approved use is specific: reducing excess abdominal fat in adults with HIV and lipodystrophy. It is not FDA approved for general weight loss, obesity treatment or routine “belly fat” reduction.
What Is Tesamorelin?
Tesamorelin is a 44-amino-acid GHRH analog modified to improve stability compared with naturally occurring GHRH. Rather than providing growth hormone directly, it acts upstream at the pituitary.
This mechanism explains why searches for tesamorelin peptide, tesamorelin benefits, tesamorelin visceral fat and tesamorelin IGF-1 often overlap. The mechanism is established, but the appropriate clinical interpretation depends heavily on the population being treated.
How Does Tesamorelin Work?
Growth hormone is naturally secreted in pulses under hypothalamic control. Tesamorelin enhances signaling through this physiological pathway rather than supplying recombinant growth hormone directly.
The current FDA label specifically notes that tesamorelin stimulates GH production and increases serum IGF-1. Because persistent elevations in IGF-1 have uncertain long-term consequences, FDA labeling recommends monitoring IGF-1 during approved therapy.
What Is Tesamorelin FDA Approved For?
This distinction is essential. Tesamorelin has stronger clinical evidence than many peptides discussed in wellness settings, but that evidence comes primarily from studies involving adults with HIV-associated lipodystrophy and excess abdominal visceral fat.
Using tesamorelin for general visceral-fat reduction, obesity, athletic performance or healthy-aging goals falls outside its FDA-approved indication.
Does Tesamorelin Reduce Visceral Fat?
Visceral adipose tissue (VAT) is different from subcutaneous fat, the fat located directly beneath the skin. Tesamorelin’s pivotal studies demonstrated preferential reductions in visceral abdominal fat in the population for which it was studied.
In a large randomized trial, visceral adipose tissue decreased approximately 15% over 26 weeks with tesamorelin while increasing in the placebo group. Another 12-month study reported sustained VAT reduction in patients who continued treatment, while visceral fat reaccumulated after tesamorelin was stopped.
A 2026 meta-analysis of randomized trials in people with HIV-associated lipodystrophy also found significant reductions in visceral adipose tissue, waist circumference and trunk fat. These findings strengthen the evidence for the approved clinical population, but they should not be automatically extrapolated to people without HIV-associated lipodystrophy.
Tesamorelin for Weight Loss: Does It Lower Body Weight?
This is one of the most important misconceptions surrounding tesamorelin for weight loss. A person can lose visceral fat without seeing a proportionate change on the scale.
Clinical evidence has focused on VAT, waist circumference and body composition—not conventional obesity treatment. Patients searching for a medication primarily to lower body weight should not assume tesamorelin is interchangeable with FDA-approved anti-obesity medications.
Tesamorelin for Belly Fat: Visceral Fat vs Subcutaneous Fat
That distinction is particularly important when patients encounter claims that tesamorelin simply “burns belly fat.” The clinical evidence is more specific than that phrase suggests.
What Does Research Show About Tesamorelin?
Visceral Adipose Tissue
A 2007 randomized trial involving more than 400 adults with HIV and abdominal fat accumulation found a 15.2% reduction in visceral adipose tissue after 26 weeks in the tesamorelin group versus an increase in placebo.
Longer-Term Treatment
Extension studies found that reductions in VAT could be maintained during continued treatment. When patients switched from tesamorelin to placebo, visceral fat tended to reaccumulate, suggesting that the effect is not necessarily permanent after discontinuation.
Liver Fat
A smaller randomized clinical trial in adults with HIV and abdominal fat accumulation found reductions in both visceral adipose tissue and liver fat over six months. This is scientifically interesting but does not create a general FDA-approved indication for fatty liver disease.
Lean Body Mass
Recent pooled analyses have reported increases in lean body mass in the studied HIV-associated lipodystrophy population. This should not be interpreted as evidence that tesamorelin is an approved or established muscle-building therapy for healthy adults.
Does Tesamorelin Increase IGF-1?
IGF-1 is involved in growth, tissue signaling and metabolism. Higher is not automatically better. The goal of medical monitoring is not simply to maximize an IGF-1 number.
The FDA label advises considering discontinuation in patients with persistent IGF-1 elevations, particularly when the clinical response is not robust.
Tesamorelin Side Effects and Safety
Potential adverse effects and safety considerations include:
- injection-site reactions
- fluid retention or edema
- arthralgia or musculoskeletal discomfort
- carpal tunnel syndrome
- elevated IGF-1
- changes in glucose tolerance
- hypersensitivity reactions
Current FDA labeling lists active malignancy, pregnancy, disruption of the hypothalamic-pituitary axis and known hypersensitivity among contraindications. Patients with a history of malignancy require careful clinical consideration.
Tesamorelin vs Sermorelin: What’s the Difference?
Read our physician guide to sermorelin. A dedicated Sermorelin vs Tesamorelin comparison will explore the differences in greater detail.
Tesamorelin vs HGH
Tesamorelin requires a functioning hypothalamic-pituitary pathway. This is one reason disruption of that axis is listed as a contraindication in FDA prescribing information.
Tesamorelin in Dallas: What Patients Should Know
At Sanjiva Medical Spa in Dallas, peptide-related care begins with medical evaluation rather than choosing a peptide from a menu. Interest in abdominal fat, body composition or metabolic health does not automatically make tesamorelin the appropriate treatment.
Evaluation may include medical history, medications, body composition, metabolic health and relevant laboratory findings. When treatment is discussed, patients should understand whether the proposed use is FDA approved or off label and what evidence supports the decision.
Explore Sanjiva Medical Spa’s approach to individualized peptide evaluation, medical oversight, laboratory review and treatment planning.
Frequently Asked Questions About Tesamorelin
What is tesamorelin used for?
Tesamorelin is FDA approved as EGRIFTA WR for reducing excess abdominal fat in adults with HIV and lipodystrophy. It is not FDA approved for general weight-loss management or routine treatment of obesity.
Is tesamorelin FDA approved?
Yes. Tesamorelin is FDA approved as EGRIFTA WR for reducing excess abdominal fat in adults with HIV and lipodystrophy. The FDA-approved indication does not include general obesity treatment, routine weight loss or cosmetic abdominal-fat reduction.
Does tesamorelin reduce visceral fat?
Yes. Randomized clinical trials show that tesamorelin reduces visceral adipose tissue in adults with HIV-associated lipodystrophy and excess abdominal fat. Evidence from that population should not automatically be extrapolated to otherwise healthy adults.
Does tesamorelin cause weight loss?
Tesamorelin is not indicated for weight-loss management. Its principal studied effect is reduction of visceral abdominal fat in adults with HIV-associated lipodystrophy rather than substantial loss of total body weight.
Does tesamorelin increase IGF-1?
Yes. Tesamorelin stimulates endogenous growth hormone production and can increase serum IGF-1. FDA prescribing information recommends monitoring IGF-1 because the effects of prolonged elevations are not fully known.
What happens when tesamorelin is stopped?
Clinical extension studies found that visceral fat tended to reaccumulate after tesamorelin was discontinued. This suggests that reductions in visceral adipose tissue may not persist after treatment stops.
Is tesamorelin the same as sermorelin?
No. Both act through the GHRH pathway, but they differ in structure, pharmacology, regulatory status and clinical evidence. Tesamorelin has a current FDA-approved indication, while there is no currently marketed FDA-approved sermorelin product in the United States.
Where can I get evaluated for tesamorelin in Dallas?
Sanjiva Medical Spa in Dallas offers physician-guided peptide evaluations. The evaluation reviews medical history, treatment goals, medications, body composition and relevant laboratory findings before determining whether tesamorelin or another approach is clinically appropriate.
Considering Peptide Therapy in Dallas?
Learn more about Sanjiva’s approach or schedule an evaluation.
Selected References
- U.S. Food and Drug Administration. EGRIFTA WR™ (tesamorelin) prescribing information. Current FDA labeling.
- Falutz J, et al. Metabolic effects of a growth hormone-releasing factor in patients with HIV. N Engl J Med. 2007;357:2359-2370.
- Falutz J, et al. Effects of tesamorelin, a growth hormone-releasing factor, in HIV-infected patients with abdominal fat accumulation: randomized placebo-controlled trial with safety extension. J Acquir Immune Defic Syndr. 2010;53:311-322.
- Stanley TL, et al. Effect of tesamorelin on visceral fat and liver fat in HIV-infected patients with abdominal fat accumulation: a randomized clinical trial. JAMA. 2014;312:380-389.
- Badran AS, et al. Body composition, hepatic fat, metabolic, and safety outcomes of tesamorelin in HIV-associated lipodystrophy: a meta-analysis of randomized controlled trials. Obes Res Clin Pract. 2026;20:2-12.
